PCI Biotech to present at the Oligonucleotide Therapeutics Society (OTS) 11th Annual Meeting
Lysaker, 13 October, 2015 – PCI Biotech will be presenting at the Oligonucleotide Therapeutics Society (OTS) 11th Annual Meeting. The event will feature the latest developments from the various oligonucleotide-based disciplines including antisense, siRNA, immunomodulatory, aptamers and micro/non-coding RNA research, presented by the leading experts in the field. The event will take place at Stadspodia, Leiden, Netherlands October 11-14th 2015.
The presentation “Photochemical internalisation (PCI) – an innovative technology for inducing endosomal escape and enhancing nucleic acid delivery in vitro and in vivo” will be held October 13th, 9:30 local time and the company will be represented by Dr. Anders Høgset, CSO. The presentation is attached below:
PCI Biotech OTS presentation Oct 2015
About PCI Biotech:
PCI Biotech is a cancer focused biopharmaceutical company headquartered in Norway and listed on the Oslo Stock Exchange (Axess). The company is developing therapeutic products based on its proprietary photochemical internalization (PCI) technology. Originating from world leading research at the Norwegian Radium Hospital, the PCI technology works by inducing triggered endosomal release and may be used to unlock the true potential of a wide array of therapeutic modalities, such as small molecules, vaccines and nucleic acids.
The company currently has a bile duct cancer program in phase I/II clinical development. Bile duct cancer is an orphan indication without any approved medicinal products and a high medical need for better local treatments. It is an indication well suited for PCI treatment, with easy light access for intraluminal surface illumination through routine endoscopic methods and an active generic drug (gemcitabine) significantly enhanced by PCI.
The company is also developing PCI as a CTL (Cytotoxic T Lymphocyte) induction technology for therapeutic and prophylactic vaccination. It has been demonstrated both in vivo and ex vivo that PCI significantly increases the number of activated antigen-specific CTLs by enhancing the MHC I antigen presentation of antigen presenting cells. When applied in the emerging field of cancer immunotherapy, PCI can be used to enhance the important cytotoxic effect of therapeutic cancer vaccines.
The PCI technology is also very well suited for intracellular delivery of nucleic acids, such as RNA therapeutics. By releasing nucleic acid compounds from endosomes where they are trapped following administration, PCI addresses one of the major bottlenecks facing this emerging and exciting field.
PCI Biotech follows a strategy to create value by improving the effect both of existing cancer drugs and by realizing the large potential in new therapeutics, including therapeutic vaccines.
Contact information:
PCI Biotech Holding ASA,Strandveien 55, N-1366Lysaker
Per Walday, CEO,pw@pcibiotech.no,Mobile: +47 917 93 429